Advertisement

Advertisement
Head and Neck Cancer

Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standard care in patients with locally advanced head and neck squamous cell carcinoma.

 

Issues in Oncology

Nearly 50% of All Cancer Deaths Worldwide Attributable to Modifiable Risk Factors

New data reported in The Cancer Atlas, Fourth Edition showed that an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors, including tobacco and alcohol use, infections, excess body weight, unhealthy diet, physical inactivity, ultraviolet radiation exposure, environmental pollutants, and occupational exposures. The report also found sharply rising rates of lung, colorectal, and breast cancers in lower-income countries; increasing rates of colorectal cancer among young adults in high-income countries; and a continuing lack of universal health coverage, which, if implemented worldwide, could save more than 7 million lives by 2030.

 

Colorectal Cancer

Predictive Biomarker Under Study in Colorectal Cancer

Researchers have uncovered a biomarker that may determine response to cytokine-induced killer-cell therapy and survival in patients with colorectal cancer, according to a recent study published by Li et al in The Journal of Immunology.

 


Advertisement
Breast Cancer
Survivorship

Breast Cancer: New Study Finds Survivors May Face Lower Risk of Alzheimer Dementia

Breast cancer survivors may have a slightly lower risk of developing Alzheimer dementia compared with cancer-free individuals, according to the results of a study published by Jeong et al in JAMA Network Open.

 

Leukemia

Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models

A combination of menin inhibition and KAT6A/7 inhibition significantly improved survival for NUP98-rearranged pediatric acute myeloid leukemia (AML) in AML model systems, even in menin inhibitor–resistant cells, according to findings published in Cancer Discovery.

 

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Gynecologic Cancers

Mailed Self-Collection HPV Tests Improve Cervical Cancer Screening Rates, Study Finds

Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world,...

Advertisement

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib (Zegfrovy), a selective EGFR tyrosine kinase inhibitor, for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award

W. Kimryn Rathmell, MD, PhD, FASCO W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role ...

The Ohio State Appoints Christian Rolfo, MD, PhD, MBA, to Lead Division of Medical Oncology

Christian Rolfo, MD, PhD, MBA Christian Rolfo, MD, PhD, MBA, has been appointed Director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James). He will assume this...

Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL

In an Australian phase II trial (COALITION) reported in the Journal of Clinical Oncology, Minson et al investigated the addition of glofitamab to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide,...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Lung Cancer

I Was Expecting to Hear I Have Heart Disease, Not Cancer

In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...

Advertisement

Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

In a National Cancer Institute phase II trial reported in The New England Journal of Medicine, Srinivasan et al investigated whether the monoclonal antibody bevacizumab in combination with the EGFR inhibitor erlotinib showed activity in patients with advanced hereditary leiomyomatosis and renal...

ASCO Post X Feed
Social Media Hub by Everwall